2025 Emerging Pharma Leaders

Listen

0:00 / 0:00

Pharm Exec unveils its new slate of rising leaders in the biopharma industry—profiling the stories of five executives steering innovative scientific and strategic pursuits in R&D, market access, and patient support.

Follow the links below to read about each selection:

(In alphabetical order)

Bryan Mazlish, Co-founder and CEO, Surf Bio

Samir Ounzain, Co-founder and CEO, HAYA Therapeutics

Bill Rush, Head of US Market Access Portfolio Management, Sanofi

Janine Sengstack, PhD, Co-founder and Chief Scientific Officer, Junevity

Amy Simon, MD, Chief Medical Officer, Beam Therapeutics

*These five individuals were chosen from a pool of nominations by the Pharmaceutical Executive Editorial staff. Selections were based on a number of criteria and review of professional accomplishments and progression of responsibilities in line with those executives inhabiting key “c-suite” functions.

Articles in this issue

2 months ago

Article

Pharmaceutical Executive: August 2025 Interactive Digital Edition

2 months ago

Article

The CAR-T Climb

2 months ago

Article

An RNA-Guided Path

2 months ago

Article

Acceleration and Ambition

2 months ago

Article

Driving Disruption in Delivery

2 months ago

Article

Building Promise from Precision

2 months ago

Article

Determined Problem-Solver

2 months ago

Article

Redefining Evidence: A Paradigm Shift to Unlock Access for Innovative Therapies

2 months ago

Article

Direct-to-Consumer Prescription Care Comes of Age

2 months ago

Article

How to Get Product Iteration Right in Healthcare

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!